Skip to content
Case report Open access

Dual-Targeted Therapy With Upadacitinib and Ustekinumab in Pediatric Refractory Perianal Crohn's Disease

Sep 2026 · ACG Case Reports Journal · Vol 13 · 0 citations · 11 references
Medicine

Abstract

ABSTRACT Perianal Crohn’s disease (pCD) is a challenging manifestation of CD. We present the case of a 17-year-old adolescent girl with severe, refractory pCD, complicated by a rectovaginal fistula, who failed multiple lines of therapy and required a temporary ileostomy. While on upadacitinib (UPA) monotherapy, she experienced a flare with magnetic resonance imaging (MRI)-confirmed perianal abscesses. The addition of ustekinumab (UST) to UPA resulted in marked improvement in clinical symptoms and radiographic resolution of perianal disease on follow-up MRI. No adverse events occurred. This case highlights dual UPA/UST therapy as a promising strategy for severe, refractory pCD in an adolescent.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.